In short
This article explores the use of EO4010, a groundbreaking cancer vaccine therapy, in clinical trials for patients with previously treated metastatic colorectal cancer. The study aims to evaluate the safety and effectiveness of EO4010 when combined with other cancer treatments, offering new hope for patients who have already undergone standard therapies.
At a glance
- Study Type
- Phase 1/2 clinical trial
- Main Treatment
- EO4010 (novel cancer vaccine therapy)
- Combination Therapies
- Nivolumab and/or Bevacizumab
- Target Condition
- Previously treated metastatic colorectal carcinoma
- Primary Objective
- Evaluate safety and tolerability of EO4010 combinations
- Secondary Objectives
- Assess immunogenicity, tumor response, and survival outcomes
- Key Eligibility Criteria
- HLA-A2 positive, advanced colorectal cancer, previous treatment history
- Study Design
- Multiple cohorts evaluating different treatment combinations
- Treatment Duration
- Expected to be completed by week 43
- Follow-up
- Safety visits at 30 and 100 days post-treatment, ongoing follow-up every 8 weeks
What is EO2318?
EO2318 is a component of a novel cancer vaccine therapy called EO4010. It is being developed as a potential treatment for patients with advanced colorectal cancer. EO2318 is classified as a microbial-derived peptide therapeutic vaccine, which means it is made from small protein fragments derived from microorganisms that can stimulate the immune system to fight cancer cells.
Medical Conditions Treated
EO2318, as part of the EO4010 vaccine, is being studied for the treatment of metastatic colorectal cancer. Specifically, it is intended for patients with: Unresectable (cannot be removed by surgery) colorectal cancer Locally advanced or metastatic colorectal cancer (cancer that has spread to other parts of the body) Cancer that has been previously treated with other therapies
How EO2318 Works
EO2318 is part of a cancer vaccine that aims to stimulate the body's immune system to recognize and attack cancer cells. It works in the following ways: Immune System Activation: The vaccine helps to activate T cells, which are important immune cells that can recognize and destroy cancer cells. Targeting Tumor Antigens: EO2318 is designed to help T cells recognize specific proteins (called tumor-associated antigens or TAAs) that are found on colorectal cancer cells. Combination Therapy: In the clinical trial, EO2318 (as part of EO4010) is being tested in combination with other cancer drugs like nivolumab (an immune checkpoint inhibitor) and bevacizumab (a drug that blocks blood vessel growth in tumors). This combination approach may enhance the overall effectiveness of the treatment.
Clinical Trial Details
EO2318 is currently being studied in a clinical trial called the "AUDREY" study. Here are some key details about the trial: Trial Phase: This is a Phase 1/2 trial, which means it is testing both the safety and potential effectiveness of the treatment. Study Design: The trial is divided into different cohorts (groups) to test various combinations of EO4010 (which includes EO2318) with other cancer drugs. Treatment Schedule: Patients will receive regular treatments and undergo various tests and procedures as outlined in the study protocol. Follow-up: After treatment, patients will have follow-up visits to monitor their health and the effects of the treatment.
Eligibility Criteria
To participate in the clinical trial for EO2318 (as part of EO4010), patients must meet certain criteria. Some key eligibility factors include: Being 18 years of age or older Having HLA-A2 positive colorectal cancer (a specific genetic marker) Having advanced colorectal cancer that has been previously treated or is not suitable for standard treatments Having a good overall health status (ECOG performance status of 0 to 1) There are also several factors that may exclude a patient from participating, such as certain previous treatments or medical conditions. A healthcare provider can provide more detailed information about eligibility.
Potential Benefits
While the effectiveness of EO2318 (as part of EO4010) is still being studied, the clinical trial aims to evaluate several potential benefits: Tumor Response: The study will measure if the treatment can shrink tumors or stop them from growing. Survival: Researchers will assess if the treatment can help patients live longer without their cancer progressing (progression-free survival) and overall survival. Immune Response: The trial will evaluate if the treatment can stimulate the immune system to recognize and attack cancer cells. It's important to note that as this is an experimental treatment, its benefits are not yet proven and may vary from patient to patient.
Safety and Side Effects
A primary goal of the clinical trial is to evaluate the safety and tolerability of EO2318 (as part of EO4010) when used alone or in combination with other cancer drugs. The researchers will closely monitor patients for any side effects or adverse reactions throughout the study. Common side effects of cancer vaccines and immunotherapies may include: Fatigue Fever Injection site reactions Flu-like symptoms However, the specific side effects of EO2318 are still being studied. Patients in the trial will be carefully monitored and should report any unusual symptoms to their healthcare team.